Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

451 results about "Tumor Sample" patented technology

Hepatocellular carcinoma molecular subtype classification and subtype-specific treatment for hepatocellular carcinoma

The invention provides a method for hepatocellular carcinoma (HCC) subtype classification and treatment. The method can include identifying one or more features associated with a hepatic epithelial cell lineage for the hepatic epithelial cell lineage. The one or more features can be specified as a representation of a molecular subtype associated with hepatocellular carcinoma (HCC), such as, for example, a bile duct-like subtype, a hepatocyte-like subtype, or a progenitor cell-like subtype. If these characteristics are detected within a tumor sample of a patient, the patient can be determined as exhibiting the molecular subtype. In addition, the treatment of the patient can be determined based on the molecular subtype exhibited by the patient. For example, treatment of the patient can include additional therapies, such as GPC3 / CD3 bispecific antibodies, to overcome subtype-specific resistance to combinatorial immunotherapies associated with the progenitor cell-like subtypes. Related systems and computer program products are also provided.
Owner:GENENTECH INC

Spatial metric measurement methods for multiplex imaging and uses in tumor sample analysis

Spatial analysis methods based on nearest neighbor analysis are provided of specific regions of tissue to describe cancer states and develop biomarkers to predict outcomes. In various embodiments, the spatial analysis methods involve an interaction radius to computationally isolate local interactions and prevent the data from being influenced by cells that are very far away. Thereby, spatial analysis of cancer tissue can be quickly and consistently performed in an automated fashion to focus on tumor-immune cell biology, which occurs at a localized level.
Owner:BC CANCER PART OF THE PROVINCIAL HEALTH SERVICES AUTHORITY +1

Somatic cell structure variation detection method based on single molecule long read length sequence chart hybrid model

The invention discloses a somatic cell structure variation detection method based on a monomolecular long-read length sequence chart hybrid model, which comprises the following steps of: extracting a read length local sequence of a target structure variation interval and a flank region thereof, constructing a local chart genome by utilizing a partial sequence alignment chart algorithm, and encoding a multi-sequence alignment result. And then, a multi-category hybrid model is combined with an expectation maximization algorithm, and clustering analysis is performed on the comparison data, so that the somatic cell structure variation category only from the tumor sample is identified. And finally, generating a consensus sequence of a somatic cell structure variation region in the tumor sample, and taking the consensus sequence as an optimization result of a local genome. Compared with an existing short-read-length sequencing method, the method has the advantages that the problems of comparison errors, low-complexity sequences and genome heterogeneity can be effectively solved, and the detection precision of somatic cell structure variation is remarkably improved. Through the application of a single-molecule long-read-length sequencing technology, more comprehensive and accurate genome information can be provided.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Method for reconstructing tumor clone heterogeneity and evolutionary relationship based on tumor DNA sequencing data

The invention belongs to the field of oncology and computational biology, and discloses a method for reconstructing tumor clone heterogeneity and evolutionary relationship based on tumor DNA sequencing data. Comprising the steps of mutation multiplicity and cancer cell fraction calculation, subcloning clustering and recognition, clustering post-processing, tumor cloning evolutionary tree inference, subcloning proportion calculation and tumor sample evolutionary tree inference. According to the method, the mutation multiplicity of SNV is calculated through the Euclidean distance to accurately represent the CCF, and the subcloning clustering result is post-processed to evaluate the credibility and rationality of the subcloning clustering result. Secondly, quickly deducing a tumor cloning evolutionary tree by adopting a greedy strategy, and calculating a subcloning proportion according to an evolutionary relationship;
Owner:DALIAN UNIV

Method for constructing tumor organoid by using stromal stem cells

The invention discloses a method for constructing a tumor organoid by using stromal stem cells, which improves the survival rate and success rate of the tumor organoid by improving the introduction of the stromal stem cells in the construction of the human tumor organoid, especially for tumor samples which fail to be cultured by the currently disclosed method. The organoid constructed by the invention can be used for analyzing biological characteristics of human tumor organoid; and a clinical tumor drug sensitivity prediction platform is established by taking a tumor organ as a model tool, so that the effectiveness of a treatment scheme is evaluated more systematically and comprehensively, and support is provided for screening an optimal individualized precise treatment scheme for a tumor patient. In addition, on the platform, screening, verification and mining can be carried out on tumor batch chemotherapy drugs or other potential anti-cancer small molecule drugs in clinical application.
Owner:SHENZHEN HOSPITAL CANCER HOSPITAL CHINESE ACAD OF MEDICAL SCI

Method for detecting metabolic reprograming of cancer towards fatty acids metabolism

The invention relates to an in vitro method for classifying a subject afflicted with a cancer as suffering from a cancer with (at risk of) a metabolic reprograming towards fatty acids oxidation including a step of assaying the activation of RelB in a tumor sample form said cancer. The inventor indeed identified the pivotal role of RelB in energy metabolism and more particularly mitochondrial respiration and fatty acid oxidation. Accordingly, the invention also relates to inhibitors of RelB activity or expression, as well as of lipid metabolism for use in the treatment of cancers showing an activated RelB.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +1

Method and system for predicting neoantigen of malignant solid tumor

The invention relates to the technical field of tumor neoantigen detection, and particularly discloses a neoantigen prediction method and system for a malignant solid tumor, and the method comprises the following steps: obtaining a tumor sample and a peripheral blood sample, and carrying out DNA and RNA sequencing; analyzing and processing to obtain DNA (Deoxyribonucleic Acid) sequencing data and RNA (Ribonucleic Acid) sequencing data; analyzing to obtain an HLA typing result and a sequence of the mutant protein; calculating to obtain related characteristic values of the new antigens; calculating a new antigen score; and intercepting the first N pieces with the highest scores to obtain a neoantigen prediction result of the malignant solid tumor. Starting from the action mechanism of the new antigens, according to key steps of the prediction process, a plurality of characteristic values are selected, a hard filtering index is not adopted, a product mode is adopted, and the score of the new antigens is calculated according to the score of the relevant characteristic values of the new antigens.
Owner:TIANJIN CANCER HOSPITAL AIRPORT HOSPITAL

Construction method and application of platinum drug sensitivity prediction model

The invention relates to the technical field of drug sensitivity prediction, and discloses a platinum drug sensitivity prediction model construction method and application thereof, and the method comprises the steps: constructing a training set; according to the training set, a plurality of candidate models are obtained through training through a plurality of machine learning algorithms; and screening the plurality of candidate models according to a preset model index to obtain at least two platinum drug sensitivity prediction models. Based on the cancer species data of the target group, the applied platinum drug type data, the immune cell infiltration level data of the tumor sample tissue and the PTC data, a plurality of high-precision platinum drug sensitivity prediction models are obtained through training by utilizing a machine learning algorithm, and the method can be used for accurately predicting the platinum drug sensitivity in combination with a hard voting method. The method is high in model prediction accuracy, suitable for people, more targeted, simple and clear in prediction result, short in service cycle and low in cost.
Owner:HARBIN MEDICAL UNIVERSITY

Methylation-based tumor data processing system

The invention relates to the technical field of tumor data processing, in particular to a methylation-based tumor data processing system. The system comprises the following modules: a methylated sample sequencing module, a sequencing difference site recognition module, a tumor gene sequence analysis module and a tumor subtype classification module, performing high-throughput sequencing on the to-be-detected clinical tumor DNA sample to obtain methylated tumor sequencing data; performing methylation level quantification on the methylated tumor sequencing data, and performing tumor difference site analysis to generate tumor difference site data; performing tumor generation key gene sequence identification according to the tumor difference site data to generate tumor methylation characteristic data; and performing tumor subtype tag identification according to the tumor methylation characteristic data to generate tumor type tag data. According to the method, accurate tumor typing is realized on the basis of tumor DNA methylation characteristic analysis, and the false negative rate of low-concentration sample detection is effectively reduced.
Owner:SHENZHEN RAPHA BIOTECHNOLOGY CO LTD

Target tumor DNA fragment screening method based on deep learning

The invention relates to a target tumor DNA fragment screening method based on deep learning, and belongs to the technical field of target tumor DNA fragment screening. A tumor DNA fragment screening model is constructed through a deep neural network, a training set is used for model establishment, and a test set is used for model performance testing. And obtaining to-be-identified positive tumor sample DNA sequencing data, carrying out positioning analysis on the to-be-identified positive tumor sample DNA sequencing data according to the trained tumor DNA fragment screening model, obtaining the position of a target tumor DNA fragment, and displaying the position according to a preset mode. According to the method, the training sample data in which a plurality of different types of tumor DNA fragments exist is processed, so that the interference of the plurality of different types of tumor DNA fragments in the same tumor training sample data on model training can be reduced to the greatest extent, the prediction precision of the model can be improved, and the screening precision of the tumor DNA fragments can be improved.
Owner:SHENZHEN RAPHA BIOTECHNOLOGY CO LTD

Texture metrics in cancer prognosis

There is provided a method for quantifying texture features in histological sample from a tumor sample, comprising:receiving a digital image of the histological sample, thendividing the digital image into a plurality of sub-areas, thenusing a trained machine learning model to predict a presence of at least one biological feature for each of the sub-areas, where a probability for the presence of the biological feature is represented by a value, thenforming a data matrix by arranging the values for the probabilities of the biological features in the same way as the sub-areas are arranged in relation to the digital image, thenapplying image analysis to the data matrix for a set of texture features, to produce a quantification of at least one texture feature.
Owner:STRATIPATH AB

Optimization of multigene analysis of tumor samples

A method of analyzing a tumor sample comprising:(a) acquiring a library comprising a plurality of tumor members from a tumor sample;(b) contacting the library with a bait set to provide selected members;(c) acquiring a read for a subgenomic interval from a tumor member from said library;(d) aligning said read; and(e) assigning a nucleotide value (e.g., calling a mutation) from said read for the preselected nucleotide position, thereby analyzing said tumor sample.
Owner:FOUNDATION MEDICINE INC

Lung cancer tumor sampling device and method

The invention relates to the technical field of medical equipment, in particular to a lung cancer tumor sampling device and method.The lung cancer tumor sampling device comprises multiple needle cores and multiple sleeves in coaxial sliding fit with the needle cores, the multiple needle cores and the multiple sleeves are in one-to-one correspondence, and the multiple needle cores are parallel; the ends, back to the sampling groove, of the sleeves are jointly connected with a shell of a hollow structure, a push plate is slidably connected into the shell in the axial direction of the needle cores, and the ends, back to the sampling groove, of the needle cores penetrate through the shell and are inserted into the shell to be connected with the push plate; and an adjusting part for driving the push plate to slide in the shell is arranged between the shell and the push plate. The problem that in the prior art, single-point sampling may miss a key mutation area, and false negative is caused is solved.
Owner:ZHEJIANG PHARMA COLLEGE

Tumor phenotype analysis method and system based on disease source database and machine learning assistance

The invention discloses a tumor phenotype analysis method and system based on a disease source database and machine learning assistance, and relates to the field of artificial intelligence, and the method comprises the steps: obtaining clinical, gene and image multi-modal feature vectors of a tumor sample, inputting a multi-modal feature fusion network, and extracting each modal path vector; performing long-distance dependency modeling on clinical and gene features to obtain a first dependency feature map, and generating a second dependency feature map in combination with the feature association strength feature map; and determining a target tumor phenotype feature vector based on the second dependency feature map and the image feature path vector, finally calculating a matching confidence degree with a to-be-selected phenotype feature vector in a tumor phenotype database, and selecting a phenotype corresponding to the highest confidence degree as a target result. Through cross-modal feature dependence modeling and disease source database matching, the accuracy and efficiency of tumor phenotype analysis are improved, and support is provided for clinical precise diagnosis and treatment.
Owner:BEIJING KEPTON PHARM TECH DEV CO LTD

Method for screening potential neoantigen of tumor from transposition element

The invention provides a method for screening a potential neoantigen of a tumor from a transposon element. The method comprises the following steps: collecting tumor tissue transcriptome sequencing data and normal tissue transcriptome sequencing data; identifying a TE transcript new type TEtrans based on a TE splicing event; performing feature analysis on the TEtrans; the TEtrans with the potential coding capability is screened out; and identifying the new antigen epitope peptide from the TEtrans: hydrolyzing all open reading frames of the to-be-selected TEtrans into 9 peptides which are mutually overlapped, removing annotated peptide fragments contained in Uniprot, defining the new antigen epitope peptide from the TEtrans according to allele typing of a tumor sample, further comparing the new antigen from the TEtrans with three common new antigens from genomic variation sources, and identifying the new antigen from the TEtrans. And screening to obtain the tumor potential new antigen. According to the invention, a brand new intergene region TE source transcript is successfully identified, and the transcript can be uniquely positioned and accurately quantified, so that a tumor specific transcript is screened as a potential tumor new antigen, and the method has huge potential in the aspect of developing tumor new antigen vaccines, especially tumors with low mutation load.
Owner:FUDAN UNIV SHANGHAI CANCER CENT

Optimization of multigene analysis of tumor samples

A method of analyzing a tumor sample comprising:(a) acquiring a library comprising a plurality of tumor members from a tumor sample;(b) contacting the library with a bait set to provide selected members;(c) acquiring a read for a subgenomic interval from a tumor member from said library;(d) aligning said read; and(e) assigning a nucleotide value (e.g., calling a mutation) from said read for the preselected nucleotide position, thereby analyzing said tumor sample.
Owner:FOUNDATION MEDICINE INC

A bone tumor clinical sample collection and temporary storage test box

InactiveCN115644943BSolve the problem of limited supportSolve the problem of low temperature aseptic protectionBio-packagingSurgical needlesBone neoplasmTumor Sample
The present invention provides a clinical sample collection and temporary storage inspection box for bone tumors, which solves the problem that too few myeloma samples are collected due to puncture sampling during the myeloma sampling process for patients, empty sampling occurs during the collection process, and the sample tissue needs to be exposed to the outside world for a short time after sampling; the present invention comprises an inspection box, a through hole is provided at the lower end of the inspection box, a positioning cylinder is coaxially fixedly connected to the upper end of the through hole, a puncture needle is coaxially connected to the lower end of the positioning cylinder, the puncture needle is a hollow structure, a through hole is provided at the lower end of the puncture needle, a cutting cylinder is connected to the positioning cylinder for sliding up and down, a lifting piston cylinder is connected above the cutting cylinder, a magnet disk is fixedly connected to the upper end of the lifting piston cylinder, a lifting frame is connected to the upper end of the lifting piston cylinder, a magnet ring matched with the magnet disk is fixedly connected to the lower end of the lifting frame, a lifting rope is coaxially fixedly connected to the upper end of the lifting piston, and the lifting rope passes through the lifting frame; the present invention has a delicate structure and is highly practical.
Owner:THE FIRST MEDICAL CENT CHINESE PLA GENERAL HOSPITAL

Use of multi-nucleotide and structural variants for improved sensitivity and specificity of circulating tumor DNA assays

Described herein are methods of preparing an enriched library of nucleic acids, comprising: (a) identifying a patient-specific panel of somatic variants present in a tumor sample from a patient, (b) generating a subset panel of somatic variants from the patient-specific panel, wherein the subset of somatic variants comprises one or more of: multi -nucleotide variants, insertions and deletions, and genomic rearrangements; (c) preparing a sample of cell-free DNA (cfDNA) fragments from the patient for sequencing; and (d) selectively enriching the cfDNA for the subset of somatic variants to generate an enriched library.
Owner:MYRIAD WOMENS HEALTH INC

Determination of cytotoxic gene signature and associated systems and methods for response prediction and treatment

ActiveUS12618115B2Medical simulationHealth-index calculationUterine carcinomaAntigen
Disclosed herein are systems, methods, and compositions for treating a subject diagnosed with, or suffering from cancer. In some embodiments, the method comprises determining whether a tumor sample from the subject includes a cytotoxic gene signature, and treating the subject based on the determination. In some embodiments, the subject has or is suspected of having a loss of heterozygosity in human leukocyte antigen (HLA) class I genes. In some embodiments, the therapy comprises one or more checkpoint inhibitors. In some embodiments, the cancer is colorectal, uterine, stomach, lung, skin, head or neck, or non-small cell lung carcinoma.
Owner:TEMPUS AI INC

Cancer-associated fibroblast subtypes for diagnosis, prognosis, and treatment

This disclosure is directed to two cancer-associated fibroblast (CAP) subtypes, namely permissive (permCAF) and restraining (restCAF), in pancreatic ductal adenocarcinoma (PDAC), mesothelioma, urothelial carcinoma, or renal cell carcinoma. Methods are disclosed that describe how to identify a tumor sample as a perCAF or a restCAF subtypes. Methods are also disclosed that use the subtypes for diagnosis, prognosis, differential treatment, and treatment.
Owner:THE UNIV OF NORTH CAROLINA AT CHAPEL HILL

Molecular typing model construction and recognition method of BRCA mutant breast cancer

The invention relates to a molecular typing model construction and identification method of BRCA mutation breast cancer. The method comprises the following steps: performing unsupervised clustering analysis on a gene with most significant change in a common transcriptome expression profile of BRCA1 / 2 mutant breast cancer to obtain an optimal clustering number, and dividing the optimal clustering number into subtypes with different clinical prognosis and molecular characteristics of the optimal clustering number; based on the clustering result, a random forest algorithm is utilized to construct a molecular typing model, the model comprises a plurality of key classification genes, and the molecular typing model is verified through a verification set and an external data set so as to ensure the accuracy, the stability and the clinical applicability of the molecular typing model. Molecular typing can be rapidly and accurately carried out according to common transcriptome sequencing data of a BRCA1 / 2 mutant breast cancer patient tumor sample, and a scientific basis is provided for selection of an individualized treatment scheme.
Owner:BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL

Products and uses thereof for predicting the sensitivity of a subject to cancer immunotherapy and for selecting optimized therapy

The present invention relates to a method of predicting, assessing or monitoring the sensitivity of a subject having a cancer to an immunotherapy, preferably to an immunotherapy combining at least two immunotherapeutic agents, and to corresponding kits and uses thereof. The method of predicting, assessing or monitoring the sensitivity of a subject having a tumor to an immunotherapy typically comprises a step of assessing, before any immunotherapeutic treatment step in the subject, the presence of CD4+CD25highCD39high T cells in a tumor sample of the subject, the presence of CD4+CD25highCD39high T cells in the tumor sample of the subject being indicative of sensitivity of the subject to the immunotherapy, and the absence of CD4+CD25highCD39high T cells in the tumor sample of the subject being indicative of resistance of the subject to the immunotherapy.
Owner:INSTITUT GUSTAVE ROUSSY +1

Somatic mutation recognition method and system based on residual network in combination with channel attention mechanism

The invention discloses a somatic mutation recognition method and system based on a residual network in combination with a channel attention mechanism, and the method comprises the steps: scanning a sequence comparison result of a tumor sample and a paired normal sample, and constructing a multi-channel feature matrix representation; a somatic mutation recognition model combining a residual network (ResNeXt) and a channel attention mechanism (SE module) is constructed, verification and fine tuning are performed by using a test set, and then the somatic mutation recognition model which is excellent in performance and suitable for resource-constrained environment deployment is obtained. The invention provides a new hybrid neural network, the network fully utilizes sequence comparison result information of a tumor sample and a paired normal sample, somatic mutation information can be extracted and learned more effectively, and mutation recognition accuracy is improved.
Owner:CHONGQING UNIV OF POSTS & TELECOMM

Nouritrophoblast-free one-step culture method of tumor infiltrating lymphocytes and application

PendingCN120173875AMammal material medical ingredientsBlood/immune system cellsTumor infiltrating lymphocyte therapyTrophoblastic cell
The invention discloses a trophoblast-free one-step culture method and application of tumor infiltrating lymphocytes, and particularly discloses a one-step amplification method of tumor infiltrating lymphocytes, which comprises the following steps: treating a tumor sample obtained from a subject into tumor segments; the tumor segments are cultured in a culture medium containing a CD3 agonist, a 4-1BB agonist and IL-2, so that an amplified tumor infiltration lymphocyte population is obtained, and the culture medium does not contain trophoblastic cells. Compared with the prior art, the method has the advantages that the required period for amplifying the tumor infiltrating lymphocytes is shorter, the cost is lower, the cell effect function is stronger, and the clinical application range of the tumor infiltrating lymphocyte therapy is widened.
Owner:BENNU BIOTHERAPEUTICS (SHANGHAI) CO LTD

Method for detecting and classifying abnormal DNA methylation fragments in cell free DNA

The invention belongs to the technical field of bioinformatics, and particularly relates to a method for detecting abnormal DNA methylation fragments from cell free DNA (cell free DNA, cfDNA) and classifying the abnormal DNA methylation fragments from the cell free DNA, and the method comprises the following steps: based on a healthy cfDNA sample and a tumor cfDNA sample, selecting methylation haplotype regions (Methylation Haplotype Block, MHB) having significant difference between the two samples by adopting seven DNA methylation measurement indexes; on the basis of the selected methylated haplotype regions with significant differences, constructing total distribution of seven DNA methylation measurement indexes in the healthy cfDNA sample and the tumor cfDNA sample, and carrying out differential analysis; seven DNA methylation measurement indexes are adopted to construct classification models for abnormal DNA methylation fragments, and the classification models of the seven abnormal DNA methylation fragments are integrated on the basis of differential analysis results of overall distribution of the seven DNA methylation measurement indexes. According to the application, the abnormal DNA methylation fragments in the cell free DNA are detected by adopting seven DNA methylation measurement indexes, and the abnormal DNA methylation fragment classification model based on the seven DNA methylation measurement indexes is integrated, so that the improvement of the sensitivity of tumor early screening is facilitated.
Owner:刘俊锋

PDC (Polycrystalline Diamond Compact) cell carrying bar code DNA (Deoxyribonucleic Acid) tag library convenient to track as well as preparation method and application thereof

The invention relates to a PDC (Polycrystalline Diamond Compact) cell carrying a bar code DNA (Deoxyribose Nucleic Acid) tag convenient to track as well as a preparation method and application thereof, and belongs to the technical field of The invention provides an isolated culture method of PDC primary cells, and provides a method for constructing recombinant PDC cells containing bar code DNA tags. According to the PDC primary cell culture system, the cell caking rate is reduced, the cell viability and the adherence rate are improved, and continuous passage to 20 generations or above can be achieved. The PDC primary cells faithfully retain the heterogeneity of clinical tumor samples in the aspects of mutation types, tumor generation and development mechanisms and the like. The bar code DNA tag introduced into the PDC cell can be detected by carrying out targeted sequencing and single cell RNA sequencing on a bar code DNA tag sequence in cell genome DNA, so that different clone groups reserved from PDX of the PDC cell line are conveniently distinguished and tracked in a high-throughput manner.
Owner:GUANGZHOU JENNIO BIOLOGICAL TECH CO LTD

An apparatus and method for detecting and analyzing the immune microenvironment of solid tumors

The present invention relates to the technical field of tumor immune microenvironment detection and analysis, and discloses an apparatus and method for detecting and analyzing the immune microenvironment of solid tumors. The apparatus for detecting and analyzing the immune microenvironment of solid tumors includes: a detection mechanism: used to contact with a tumor sample or puncture a part of the tumor sample and upload data for operators to analyze; a transportation and cleaning mechanism integrating transportation, cleaning and adjustment functions: cleaning both sides of the sample synchronously during transportation and adapting to different sample sizes; a clamping and turning mechanism: clamping the sample and turning it to position to expose the cleaning surface; a collection component: detachably recovering the shed impurities; a wiping component: used to clean the detection area of the detection mechanism after detection to prevent residual substances from affecting subsequent detection results. The transportation and cleaning mechanism of the present invention can automatically clean the impurities outside the sample while transporting the tumor sample, and can also adjust according to samples of different sizes, improving the accuracy of subsequent detection.
Owner:JINAN UNIVERSITY

A tumor sampling device for easily separating tumors

The present invention discloses a tumor sampling device that is convenient for separating tumors, and relates to the technical field of tumor sampling equipment, including: a sampling tube, the sampling tube is arranged in a needle tube and can move along the length direction of the needle tube between a first position and a second position, a separation mechanism is embedded in the sampling tube and arranged near the bottom of the sampling tube, the separation mechanism can separate the tumor sample from the tumor, an adsorption sampling mechanism penetrates the needle tube and is connected to the sampling tube, and the adsorption sampling mechanism can suck the tumor sample out of the sampling tube. During the tumor sampling process, the sampling tube is first inserted into the tumor, and then the tumor sample is separated from the tumor by the separation mechanism. Although there is a sequential operation sequence, the needle does not need to be pulled out during the operation, and the position of the sampling tube after being inserted into the tumor does not need to be changed. As a whole, tumor sampling can be achieved in one operation, avoiding tumor debris from falling into non-tumor areas and reducing the risk of tumor metastasis.
Owner:AFFILIATED HOSPITAL OF NANTONG UNIV +1

A cold chain transport insulation box

The present invention relates to the field of storage technology, and specifically to a cold chain transport insulation box, including a temporary storage box, a through opening is opened at the bottom of the temporary storage box, a heat insulation component is arranged inside the temporary storage box, the heat insulation component includes a heat insulation board and a cover board, the heat insulation component is used to block the alternation of cold and hot air flows, a closing component is arranged inside the temporary storage box, and the closing component is used to control the opening and closing of the through opening. The present invention controls the movement of a cold storage box so that the cold storage box passes through the through opening and extends out from the inside of the device, so that the cold storage box can be replaced when the device is locked, thereby preventing unauthorized personnel from arbitrarily contacting or opening samples, ensuring the safety and integrity of the samples, and by adjusting the position of the heat insulation board, the heat insulation board can be used to separate the cold storage box and the tumor samples stored inside the device, so that the alternation of cold and hot air flows at the through opening can be blocked by the heat insulation board, thereby preventing the alternation of cold and hot air flows from having a significant impact on the temperature inside the device.
Owner:LIANYUNGANG HAIZHIKANG INSULATION NEW MATERIALS CO LTD

Tumor puncture sampling device

InactiveCN222075228UEasy to cutPuncture sampling is convenientSurgical needlesTumor SampleKnife blades
The utility model discloses a tumor puncture sampling device which comprises a shell and a preparation mechanism installed on one side of the shell, the preparation mechanism comprises an adjusting assembly and a puncture assembly, and the adjusting assembly comprises a motor, a worm, a worm gear, a rotating shaft, a first connecting plate and a sliding rail; the tumor puncture sampling device is provided with a needle core and a needle shell, a triangular clamping plate can be extruded by pressing a pressing plate, so that a spring is rebounded, the rebounding force can drive the needle core to be recycled, a tumor sample is rapidly cut when an annular cutting blade at the top of the needle core returns, and the cut tumor sample is reserved in a groove; the whole arrangement is more convenient for cutting a sample, and avoids sampling failure caused by the fact that the needle tube of the puncture sampling device is sucked by connecting equipment capable of generating negative pressure, such as an injector and the like, and then the needle tube is drawn out after the needle tube is punctured, and tumor tissues in the needle tube are still in a growth connection state with the tumor and are extremely easy to fall off when the needle tube is drawn out.
Owner:桂仲璇